Climb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPS

Climb Bio (NASDAQ:CLYM) announced its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02, Zacks reports.

Climb Bio Trading Down 1.5 %

Climb Bio stock traded down $0.02 during midday trading on Tuesday, reaching $1.30. 104,583 shares of the company’s stock were exchanged, compared to its average volume of 379,421. The firm has a 50-day moving average price of $1.60. The company has a market cap of $87.39 million, a price-to-earnings ratio of -0.61 and a beta of -0.19. Climb Bio has a 52 week low of $1.20 and a 52 week high of $11.55.

Wall Street Analyst Weigh In

CLYM has been the subject of a number of analyst reports. Leerink Partnrs upgraded Climb Bio to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on shares of Climb Bio in a report on Monday, December 2nd. They set an “outperform” rating and a $10.00 target price on the stock.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.